Maintenance of clinical response and consistent safety profile with up to three years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2019.11.040
Abstract: BACKGROUND Long-term maintenance treatment is required for patients with psoriasis. OBJECTIVES To evaluate the efficacy and safety of guselkumab in patients with moderate-to-severe psoriasis through three years of treatment. METHODS In two on-going, phase 3… read more here.
Keywords: three years; treatment; safety; voyage voyage ... See more keywords